DexCom (NASDAQ: DXCM) is one of 81 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its rivals? We will compare DexCom to related companies based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.
Insider & Institutional Ownership
65.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 1.7% of DexCom shares are held by insiders. Comparatively, 11.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This table compares DexCom and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for DexCom and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DexCom presently has a consensus price target of $70.69, indicating a potential upside of 29.33%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 5.27%. Given DexCom’s stronger consensus rating and higher probable upside, equities research analysts plainly believe DexCom is more favorable than its rivals.
Risk and Volatility
DexCom has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500. Comparatively, DexCom’s rivals have a beta of 1.00, suggesting that their average stock price is 0% more volatile than the S&P 500.
Earnings and Valuation
This table compares DexCom and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|DexCom||$573.30 million||-$65.60 million||-95.89|
|DexCom Competitors||$975.11 million||$120.37 million||172.41|
DexCom’s rivals have higher revenue and earnings than DexCom. DexCom is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
DexCom Company Profile
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company’s markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.